NXL
Nexalin Technology Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
nexalin technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. nexalin’s patented waveform (1 u.s. patent #6904322b2) the nexalin device produces a patented waveform that provides transcranial electrical stimulation (tes). in clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. the nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. additionally, the fda classification of the device for clinical trials places it into a non-significant risk (low risk device) category. natural frequency will promote balance in the brain by normalizing neurochemistry.this effectiveness of this unique therapy is long lasting and fda approved. laboratory and clinical evidence suggest that nexalin’s patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals
Market Cap: 3.87 Million
Primary Exchange: NASDAQ
Shares Outstanding: 7.44 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
Ethical Flags
Longest drawdown: 359 trading days
From: 2022-12-01 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|